Anuh Pharma Ltd (ANUHPHR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 905552,
    "name": "Anuh Pharma",
    "stock_name": "Anuh Pharma",
    "full_name": "Anuh Pharma Ltd",
    "name_url": "stocks-analysis/anuh-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "79.43",
    "chg": 7.43,
    "chgp": "10.32%",
    "dir": 1,
    "prev_price": "72.00",
    "mcapval": "747.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 506260,
    "symbol": "ANUHPHR",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE489G01022",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "1.06 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/anuh-pharma-905552-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Anuh Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-anuh-pharma-technically-bullish-or-bearish-3743024",
        "imagepath": "",
        "date": "2025-12-03 08:42:46",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Technical Trend Shift and Moving Averages</strong></p>\n<p>As of 2 December 2025, Anuh Pharma’s technical trend has shifted from mildly bearish to outright bearish. This change reflects a deterioration in the stock’s momentum and signals increased selling pressure. The daily moving averages reinforce this view, showing a bearish alignment that typically indicates downward price movement in the near term. Moving averages are a key tool for traders to identify trend direction, and a bearish stance here suggests that the stock is struggling to maintain upward momentum.</p>\n<p><strong>MACD and Momentum Indicators</strong></p>\n<p>The Moving Average Convergence Divergence (MACD) indicator, a popular momentum oscillator, presents a mixed but predominantly negative picture. On a weekly basis, the MAC..."
      },
      {
        "title": "Anuh Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-technical-momentum-shifts-amid-bearish-signals-3742938",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AnuhPharma_technicaldot_3742938.png",
        "date": "2025-12-03 08:07:05",
        "description": "Anuh Pharma, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across various timeframes. Recent evaluation adjustments highlight a transition in the stock’s technical trend, prompting a closer examination of its price action and indicator readings amid broader market conditions."
      },
      {
        "title": "Anuh Pharma’s Market Assessment Shifts Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/anuh-pharma-stock-rating-upgraded-to-sell-amid-mixed-technical-and-financial-signals-3740721",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AnuhPharma_mojoScore_3740721.png",
        "date": "2025-12-02 08:48:13",
        "description": "Anuh Pharma has experienced a revision in its market evaluation following a complex interplay of financial performance, valuation metrics, and technical indicators. Despite recent quarterly setbacks and underperformance relative to broader indices, subtle shifts in technical trends and promoter activity have influenced the company’s overall market assessment."
      },
      {
        "title": "Anuh Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-technical-momentum-shifts-amid-mixed-market-signals-3740257",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AnuhPharma_technicaldot_3740257.png",
        "date": "2025-12-02 08:09:33",
        "description": "Anuh Pharma, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces. Recent price movements and technical indicators reveal a nuanced picture of the stock’s near-term trajectory, with mixed signals from key momentum and trend-following tools."
      },
      {
        "title": "How has been the historical performance of Anuh Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-anuh-pharma-3739322",
        "imagepath": "",
        "date": "2025-12-01 23:24:48",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the seven-year period ending March 2025, Anuh Pharma’s net sales have shown a robust upward trend, rising from ₹320.66 crores in 2019 to ₹661.51 crores in 2025. This represents more than a doubling of sales, reflecting the company’s expanding market presence and operational scale. The total operating income mirrors this growth, with no other operating income reported, indicating that core business activities are the primary revenue drivers.</p>\n<p>Despite fluctuations in raw material costs and other expenses, the company has maintained a positive operating profit margin. Operating profit before other income (PBDIT excl OI) increased from ₹29.53 crores in 2019 to ₹60.90 crores in 2025, although the margin percentage saw some variability, p..."
      },
      {
        "title": "Why is Anuh Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-anuh-pharma-fallingrising-3729928",
        "imagepath": "",
        "date": "2025-11-26 01:16:52",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Anuh Pharma’s shares have been on a consistent slide over the past week, registering a loss of 4.37%, significantly underperforming the Sensex, which remained nearly flat with a marginal decline of 0.10% during the same period. This negative momentum extends over longer horizons as well, with the stock down 11.29% in the last month, contrasting with the Sensex’s modest gain of 0.45%. Year-to-date figures reveal a stark divergence, with Anuh Pharma falling 31.72% while the broader market has advanced by 8.25%. Even over the past year, the stock has declined by 22.83%, whereas the Sensex has appreciated by 5.59%. These figures underscore a sustained period of underperformance relative to the benchmark index.</p>\n<p><strong>Technical Indi..."
      },
      {
        "title": "Anuh Pharma Faces Significant Selling Pressure with 27.42% Year-to-Date Loss Amid Poor Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-faces-significant-selling-pressure-with-2742-year-to-date-loss-amid-poor-performance-3700913",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AnuhPharma_only_sellers_3700913.png",
        "date": "2025-11-14 09:51:01",
        "description": "Anuh Pharma Ltd is experiencing notable selling pressure, continuing a trend of losses. The stock has declined significantly over various time frames, contrasting sharply with the Sensex's performance. Factors contributing to this trend include underperformance relative to its sector and trading below key moving averages."
      },
      {
        "title": "How has been the historical performance of Anuh Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-anuh-pharma-3694135",
        "imagepath": "",
        "date": "2025-11-12 23:21:44",
        "description": "Answer:\nThe historical performance of Anuh Pharma shows a steady growth in net sales and profitability over the years, with some fluctuations in costs and margins.\n\nBreakdown:\nAnuh Pharma's net sales increased from 486.65 Cr in Mar'22 to 661.51 Cr in Mar'25, reflecting a consistent upward trend. Total operating income followed a similar trajectory, rising from 486.65 Cr in Mar'22 to 661.51 Cr in Mar'25. However, the raw material costs peaked at 489.73 Cr in Mar'24 before declining to 463.28 Cr in Mar'25. Operating profit (PBDIT) saw a decline from 87.24 Cr in Mar'24 to 70.36 Cr in Mar'25, while profit before tax also decreased from 78.31 Cr to 61.01 Cr in the same period. Profit after tax mirrored this trend, dropping from 60.06 Cr in Mar'24 to 47.35 Cr in Mar'25. The company's total assets grew from 347.17 Cr in Mar'22 to 504.55 Cr in Mar'25, and total liabilities increased from 347.17 Cr to 504.55 Cr duri..."
      },
      {
        "title": "Anuh Pharma Faces Technical Shift Amidst Declining Stock Performance and Rising Promoter Confidence",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/anuh-pharma-stock-downgraded-to-strong-sell-amid-declining-performance-3688629",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AnuhPharma_mojoScore_3688629.png",
        "date": "2025-11-11 08:42:01",
        "description": "Anuh Pharma, a microcap in the Pharmaceuticals & Biotechnology sector, has experienced a recent evaluation adjustment, indicating a shift in its technical outlook. The company has faced performance challenges, including a notable year-to-date decline, while promoter confidence appears to be rising with increased stakeholder holdings."
      }
    ],
    "total": 5103,
    "sid": "905552",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/anuh-pharma-905552"
  },
  "announcements": [
    {
      "caption": "Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR)",
      "datetime": "21-Jan-2026",
      "details": "Disclosure Under Regulation 30 of the SEBI LODR regarding Assessment Order received under Section 143(3) read with Section 263 and 144B of the Income Tax Act 1961.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "12-Jan-2026",
      "details": "Compliance Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 31st December 2025 received from Bigshare Services Private Limited Registrar and Share Transfer Agent (RTA) of the Company.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "25-Dec-2025",
      "details": "Intimation regarding the closure of Trading Window for dealing in Securities of the Company shall remain closed from Thursday 01st January 2026 till the expiry of 48 hours after the declaration of Un-Audited Financial Results for the Quarter Ended 31st December 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has declared <strong>30%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has announced <strong>5:10</strong> stock split, ex-date: 31 Jul 06",
          "dt": "2006-07-31",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 15 Jul 25",
          "dt": "2025-07-15",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Anuh Pharma technically bullish or bearish?

2025-12-03 08:42:46

Technical Trend Shift and Moving Averages As of 2 December 2025, Anuh Pharma’s technical trend has shifted from mildly bearish to outright bearish. This change reflects a deterioration in the stock’s momentum and signals increased selling pressure. The daily moving averages reinforce this view, showing a bearish alignment that typically indicates downward price movement in the near term. Moving averages are a key tool for traders to identify trend direction, and a bearish stance here suggests that the stock is struggling to maintain upward momentum. MACD and Momentum Indicators The Moving Average Convergence Divergence (MACD) indicator, a popular momentum oscillator, presents a mixed but predominantly negative picture. On a weekly basis, the MAC...

Anuh Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-12-03 08:07:05

Anuh Pharma, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across various timeframes. Recent evaluation adjustments highlight a transition in the stock’s technical trend, prompting a closer examination of its price action and indicator readings amid broader market conditions.

Anuh Pharma’s Market Assessment Shifts Amid Mixed Financial and Technical Signals

2025-12-02 08:48:13

Anuh Pharma has experienced a revision in its market evaluation following a complex interplay of financial performance, valuation metrics, and technical indicators. Despite recent quarterly setbacks and underperformance relative to broader indices, subtle shifts in technical trends and promoter activity have influenced the company’s overall market assessment.

Anuh Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-12-02 08:09:33

Anuh Pharma, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces. Recent price movements and technical indicators reveal a nuanced picture of the stock’s near-term trajectory, with mixed signals from key momentum and trend-following tools.

How has been the historical performance of Anuh Pharma?

2025-12-01 23:24:48

Revenue and Profitability Trends Over the seven-year period ending March 2025, Anuh Pharma’s net sales have shown a robust upward trend, rising from ₹320.66 crores in 2019 to ₹661.51 crores in 2025. This represents more than a doubling of sales, reflecting the company’s expanding market presence and operational scale. The total operating income mirrors this growth, with no other operating income reported, indicating that core business activities are the primary revenue drivers. Despite fluctuations in raw material costs and other expenses, the company has maintained a positive operating profit margin. Operating profit before other income (PBDIT excl OI) increased from ₹29.53 crores in 2019 to ₹60.90 crores in 2025, although the margin percentage saw some variability, p...

Why is Anuh Pharma falling/rising?

2025-11-26 01:16:52

Recent Price Movement and Market Context Anuh Pharma’s shares have been on a consistent slide over the past week, registering a loss of 4.37%, significantly underperforming the Sensex, which remained nearly flat with a marginal decline of 0.10% during the same period. This negative momentum extends over longer horizons as well, with the stock down 11.29% in the last month, contrasting with the Sensex’s modest gain of 0.45%. Year-to-date figures reveal a stark divergence, with Anuh Pharma falling 31.72% while the broader market has advanced by 8.25%. Even over the past year, the stock has declined by 22.83%, whereas the Sensex has appreciated by 5.59%. These figures underscore a sustained period of underperformance relative to the benchmark index. Technical Indi...

Anuh Pharma Faces Significant Selling Pressure with 27.42% Year-to-Date Loss Amid Poor Performance

2025-11-14 09:51:01

Anuh Pharma Ltd is experiencing notable selling pressure, continuing a trend of losses. The stock has declined significantly over various time frames, contrasting sharply with the Sensex's performance. Factors contributing to this trend include underperformance relative to its sector and trading below key moving averages.

How has been the historical performance of Anuh Pharma?

2025-11-12 23:21:44

Answer: The historical performance of Anuh Pharma shows a steady growth in net sales and profitability over the years, with some fluctuations in costs and margins. Breakdown: Anuh Pharma's net sales increased from 486.65 Cr in Mar'22 to 661.51 Cr in Mar'25, reflecting a consistent upward trend. Total operating income followed a similar trajectory, rising from 486.65 Cr in Mar'22 to 661.51 Cr in Mar'25. However, the raw material costs peaked at 489.73 Cr in Mar'24 before declining to 463.28 Cr in Mar'25. Operating profit (PBDIT) saw a decline from 87.24 Cr in Mar'24 to 70.36 Cr in Mar'25, while profit before tax also decreased from 78.31 Cr to 61.01 Cr in the same period. Profit after tax mirrored this trend, dropping from 60.06 Cr in Mar'24 to 47.35 Cr in Mar'25. The company's total assets grew from 347.17 Cr in Mar'22 to 504.55 Cr in Mar'25, and total liabilities increased from 347.17 Cr to 504.55 Cr duri...

Anuh Pharma Faces Technical Shift Amidst Declining Stock Performance and Rising Promoter Confidence

2025-11-11 08:42:01

Anuh Pharma, a microcap in the Pharmaceuticals & Biotechnology sector, has experienced a recent evaluation adjustment, indicating a shift in its technical outlook. The company has faced performance challenges, including a notable year-to-date decline, while promoter confidence appears to be rising with increased stakeholder holdings.

View All News